Subcutaneous administration of sermorelin has demonstrated efficacy in treating prepubertal children with idiopathic growth hormone deficiency, inducing catch-up growth and sustained height velocity over 12 months
With energy expenditure scaled and fat storage adjusted, a few users experience a loss of 18 to 40 kilograms (40 to 87 pounds) over time, but it varies based on their individual diet and activity
Human clinical development was limited, and the postoperative ileus trial program did not establish an approved use
Symptoms include intense burning or stinging at the site, skin that shifts from pale to red to blistered, and in severe cases, tissue death
CJC-1295 without Drug Affinity Complex (NO DAC), also known as Modified GRF 1-29, is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids with four strategic substitutions designed to enhance stability
Ipamorelin is a GHRP, that is, a growth-hormone-releasing peptide, and acts at the ghrelin receptor GHS-R1a